Identification of an epigenetic biomarker predicting the response to therapy with APG101 in glioblastoma
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: APG101, a fully human fusion protein consisting of the extracellular domain of CD95 and the Fc-d...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
11 October 2016
|
| In: |
Annals of oncology
Year: 2016, Jahrgang: 27 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw363.81 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1093/annonc/mdw363.81 Verlag, kostenfrei, Volltext: https://academic.oup.com/annonc/article/27/suppl_6/133P/2798859 
|
| Verfasserangaben: | M. Thiemann, C. Gieffers, C. Kunz, J. Sykora, C. Merz, H. Fricke, B. Wiestler, W. Wick |
| Zusammenfassung: | © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: APG101, a fully human fusion protein consisting of the extracellular domain of CD95 and the Fc-domain of an IgG, has been developed by Apogenix. It was confirmed as a potent inhibitor of CD95L induced invasion of glioblastoma cells in vitro. In a randomized phase 2 study in glioblastoma patients with 1st or 2nd relapse the combined therapy of APG101 plus radiotherapy (RT) was found to be superior to RT alone in a clinically relevant order of magnitude in all efficacy endpoints (i.e. PFS-6, PFS and OS). At the same time APG101 exhibited an excellent safety profile and was well tolerated. The presented data summarizes the identification of a predictive biomarker.Methods: To identify potential biomarkers we used available tissue sections originating... |
|---|---|
| Beschreibung: | Gesehen am 15.11.2017 |
| Beschreibung: | Online Resource |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw363.81 |